Levosimendan is a calcium sensitizer and adenosine triphosphate-dependent potassium channel opener, which exerts sustained hemodynamic, symptomatic, and organ-protective effects.
As a calcium sensitizer and inodilator that augments cardiac contractility without increasing myocardial oxygen demand or exacerbating ischaemia, levosimendan may be well configured to deliver inotropic support in cases of acute heart failure (AHF).
Aims: Levosimendan improves haemodynamics in acute decompensated heart failure (HF). However, it is increasingly used for repetitive or intermittent infusions in advanced but stable chronic HF, without clear indication...
Pulmonary hypertension is a multifactorial disease with a high morbidity and mortality.
Intermittent levosimendan improved LVEF and decreased hospitalizations in advanced heart failure and represents a therapeutic option for patients whose disease is worsening.
The longer survival of patients with Duchenne muscular dystrophy due to advances in clinical care has increased the incidence of Duchenne muscular dystrophy-associated cardiomyopathy, a nearly consistent feature in the third decade...
Despite using vasoactive and PH specific therapies, the in-hospital mortality of severe pulmonary hypertension (PH) with right heart failure (RHF) is high.
Acute decompensated heart failure (ADHF) is associated with high morbidity and mortality.
Objective: Simendan is a calcium sensitizer that enhances myocardial contractility but does not affect ventricular diastole.
Background: Acute heart failure (AHF) after ST-segment elevation myocardial infarction (STEMI) is usually treated with inotropic support or vasoactive medications.